Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ICON plc (NASDAQ: ICLR) reported its Q1 2023 financial results with net business wins of $2,415 million and a book-to-bill ratio of 1.22. Revenues reached $1,978.6 million, up 4.0% year-over-year. The adjusted EBITDA stood at $399.1 million, 20.2% of revenue, reflecting a 17.2% increase. GAAP net income was $116.7 million, or $1.41 per share. The company reaffirmed its full-year 2023 revenue guidance in the range of $7,940 - $8,340 million and adjusted EPS guidance of $12.40 - $13.05, indicating a year-on-year growth of 5.5% to 11.1%. Cash flow from operations amounted to $175.5 million, with a net debt of $4.2 billion and a debt-to-adjusted EBITDA ratio of 2.8x.
ICON plc (NASDAQ: ICLR) has announced that it will release its financial results for Q1 2023 after market close on April 26, 2023. A conference call and webcast to discuss these results will occur on April 27, 2023, at 8:00 AM ET. The company, headquartered in Dublin, employs approximately 41,100 people across 111 locations in 53 countries, focused on healthcare intelligence and clinical research.
The press release emphasizes the importance of these financial results and cautions that forward-looking statements are subject to risks and uncertainties, including the impact of COVID-19 and market conditions.
LEO Pharma and ICON plc (NASDAQ: ICLR) have announced a strategic partnership aimed at enhancing patient-centric clinical trial execution. This initiative, dubbed PACE, seeks to address current clinical development challenges by improving access to innovative dermatology treatments. The partnership will utilize a hybrid outsourcing model, allowing for scalable efficiencies in clinical trials, decentralized clinical trials, and leveraging ICON's extensive resources. This collaboration aligns with LEO Pharma's 2030 strategy, focusing on delivering treatments faster and supporting sustainable business practices.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that CFO Brendan Brennan will present at the 2023 Citi Healthcare Conference on March 2, 2023, at 2pm ET. Additionally, CEO Steve Cutler will present at the Barclays Global Healthcare Conference on March 15, 2023, starting at 1:35pm ET. Both presentations will be available via live webcast, with links posted on ICON's investor relations website. As of December 31, 2022, ICON employed approximately 41,100 staff across 111 locations in 53 countries, focused on advancing clinical research for various healthcare sectors.